shutterstock_2094533392_michael_vi

Michael Vi / Shutterstock.com

6 September 2022AmericasMuireann Bolger

Vidal steps up scrutiny of Fintiv rule-based decisions

Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

USPTO urges Vidal review of Arthrex petition

19 May 2022 The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

More on this story

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

USPTO urges Vidal review of Arthrex petition

19 May 2022 The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

More on this story

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

USPTO urges Vidal review of Arthrex petition

19 May 2022 The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

More features

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court